Singapore-headquartered digital health and data analytics company, Holmusk, signed a Memorandum of Understanding (MoU) with Janssen (China) Research & Development Center, Xi’an-Janssen, to explore the development of a digital mental health strategy in China.
Based on the MoU, Holmusk and Xi’an-Janssen propose to focus on generating insights from real-world data on depression and other mental health disorders to develop novel solutions to address the increasing burden of disease in China. The two organizations would also identify areas of unmet need that a digital platform can enhance, and define the supporting, prioritized functionality based on the Janssen Neuroscience portfolio in China.
Holmusk’s experience in digital therapeutics and deep analytics will be used to develop and implement a competitive, comprehensive solution for mental health in China, with an initial focus on depression. The combination of Holmusk’s mental health platform and Janssen’s expertise and network will be used to inform future, targeted management of wellness-oriented consumers, as well as mental health consumers.
As mental health issues are still a relatively taboo topic to address, especially in Asia, the use of digital tools and platforms can help alleviate the increasing burden of mental health conditions. According to Nawal Roy, founder and chief executive officer of Holmusk, working with Janssen will allow Holmusk to develop critical solutions for individuals with mental health disorders.
Holmusk is a digital health and data analytics company focused on solving complex problems in health care. Holmusk leverages technology and data science to accelerate research and improve outcomes for people with chronic diseases and behavioral health disorders.
Xi’an Janssen is Johnson & Johnson’s pharmaceutical subsidiary. Since its inception in 1985, Xi’an Janssen has been committed to the introduction and production of high quality innovative products to meet the growing demand for medical and health. These products cover areas such as mental health, neurological disease, neoplastic disease, immune disease, gastrointestinal disease, fungal disease and infectious disease.
This was reported by MobiHealthNews on June 20, 2019.
Contact information: Xi’an Janssen Pharmaceutical Company, Ltd., 14th Floor, Building 3, Huamao Center, 77 Jianguo Road, Chaoyang District, Beijing 100025; 010-58218888; Website: www.xian-janssen.com.cn/en